Breaking News
Get 40% Off 0
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks
Close

Phaxiam Therapeutics SA (PHXM)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
2.9050 -0.0450    -1.53%
03:57:03 - Real-time Data. Currency in EUR ( Disclaimer )
Type:  Equity
Market:  France
ISIN:  FR001400K4B1 
  • Volume: 364
  • Bid/Ask: 0.0000 / 0.0000
  • Day's Range: 2.9050 - 2.9500
Phaxiam Therapeutics 2.9050 -0.0450 -1.53%

PHXM User Rankings

 
Users ranking according to the performance of their sentiments for the Phaxiam Therapeutics SA stock.
RankUsernameTotalClosedWinningWin %Chg. %
1Lounes Kahouadji111100+349.18%
2Dil Naj111100+334.87%
3Louis Enderlin66233.33+319.44%
4Geoffrey Vitti55360+300.03%
5Matthieu Merit111100+278.25%
6Azra Azra111100+271.06%
7Moi Bonjour111100+269.05%
8romain kollar111100+266.09%
9Arezki SEHAD111100+12.49%
10Aubry Ville111100+10.64%
11MISSET JP111100+9.09%
12florent bussiere111100+3.4%
13Don Simon111100+2.99%
14Lucas Matti111100+2.91%
15Victim Bogoss111100+1.64%
16Jordan Corleone1000+1.21%
17Christophe Paternesi111100+0.11%
18Jean Georges Philipps11000%
19Ve Bor11000%
20Clement Sou32150-0.21%
21Erasmus Gestion1100-1.52%
22Christophe Lefevre1100-2.22%
23Hugues Privé1100-2.25%
24Wesley Bruins1100-2.79%
25Alessandro Spettante1100-2.89%
26Brice Ferrand1100-2.92%
27Thomas WUEST1100-2.96%
28Didier Lamine1100-6.43%
29Vince Kedge1100-6.78%
30Arnaud Descamps1100-6.82%
31Arnaud HOUZÉ1100-7.39%
32gerard desprets1100-8.67%
33Dorian Jaumotte1100-10.34%
34Marc Lamour1100-11.65%
35ali laouadi1100-12.96%
36Etienne CHARIER1100-13.45%
37vincent vollmer1100-14.29%
38Muammer KAPCI1100-14.6%
39CHARLES-GERVAIS GUY1100-15.01%
40Marie Desalbres1100-17.93%
41Patricia Scorneau1100-18.37%
42Fordman Ford1100-26.3%
43Jimmy Martin1100-26.45%
44Lucas Matti2200-27.02%
45David MERLIN1100-27.97%
46Laurent Zerat109111.11-52.71%
47Green Giant1100-336.26%
48Lionel Sery33133.33-603.23%
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

PHXM Comments

Write your thoughts about Phaxiam Therapeutics SA
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Michael Corrao
Michael Corrao Sep 04, 2021 8:35PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
WEBINAR ON ERYASPASE IN PANCREATIC CANCER (SEPTEMBER 1, 2021)ERYTECH TO PARTICIPATE IN THE CITI 16TH ANNUAL BIOPHARMA CONFERENCE(September 8 2021 through September 10, 2021)ERYTECH HOSTING KEY OPINION LEADER WEBINAR ON ERYASPASE IN PANCREATIC CANCERERYTECH Hosting Key Opinion Leader Webinar on Eryaspase in Pancreatic Cancer(September 1 2021)ERYTECH GRANTED U.S. FDA FAST TRACK DESIGNATION FOR ERYASPASE IN HYPERSENSITIVE ALL(July 29, 2021)Erytech is starting the push for sales, fda approval by the end of the month if not sooner. After fda approval eryteck will hit the ceiling.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email